<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031278</url>
  </required_header>
  <id_info>
    <org_study_id>C005</org_study_id>
    <secondary_id>C005</secondary_id>
    <secondary_id>A8501020</secondary_id>
    <nct_id>NCT00031278</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of CPG 7909 and Herceptin is
      safe and effective in the treatment of metastatic breast cancer.

      RATIONALE: There is preclinical data that supports the hypothesis that CPG 7909 may
      potentiate the action of Herceptin. This Phase I/II study is designed to evaluate the safety
      and efficacy of the combination treatment of CPG 7909 and Herceptin in patients with
      metastatic breast cancer who have previously been treated with Herceptin and chemotherapy.

      SCHEDULE: Patients will receive CPG 7909 weekly for up to six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II part of study not initiated because the development plan modified the route of
      administration to subcutaneous injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: To evaluate the safety, tolerability and and MTD of several dose levels of CPG 7909 of CPG 7909 in combination with the standard Herceptin® treatment in patients with metastatic breast cancer</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Evaluate tumor response and safety of CPG 7909 in combination with Herceptin® in patients with metastatic breast cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: To evaluate tumor response, duration of response, time to disease progression, and survival time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: To evaluate duration of response, time to disease progression, and survival time</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Carcinoma, Metastatic Breast</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01 mg/kg CPG 7909 plus Herceptin®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.04 mg/kg CPG 7909 plus Herceptin®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.16 mg/kg CPG 7909 plus Herceptin®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.32 mg/kg CPG 7909 plus Herceptin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909</intervention_name>
    <description>Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>PF-3512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909</intervention_name>
    <description>Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>PF-3512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909</intervention_name>
    <description>Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>PF-3512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909</intervention_name>
    <description>Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>PF-3512676, ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin®</intervention_name>
    <description>Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA Inclusion Criteria

          -  Histologically confirmed breast cancer with metastases.

          -  Tumor that has overexpression of HER2 as documented by being either FISH-positive or
             HER2/neu 3+ confirmed by immunohistochemistry.

          -  Patients must be candidates for single agent Herceptin treatment according to the
             Herceptin® label.

        Exclusion Criteria

          -  Any prior therapy with anthracycline + Herceptin®.

          -  Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure,
             myocardial infarction within the past 6 months, unstable angina; coronary angioplasty
             within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or
             left ventricular ejection fraction &lt; 50%.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Network, Inc.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at Univ. of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Pittsburgh Cancer Institute, Magee Women's Hosp.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2002</study_first_submitted>
  <study_first_submitted_qc>February 28, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2002</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>CPG 7909</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

